KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $8.2 million.

  • Amneal Pharmaceuticals' Share-based Compensation rose 15.57% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 16.69%. This contributed to the annual value of $27.8 million for FY2024, which is 3.53% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Share-based Compensation of $8.2 million as of Q3 2025, which was down 0.66% from $8.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Share-based Compensation high stood at $8.3 million for Q2 2025, and its period low was $5.3 million during Q1 2021.
  • Over the past 3 years, Amneal Pharmaceuticals' median Share-based Compensation value was $7.1 million (recorded in 2024), while the average stood at $7.1 million.
  • In the last 5 years, Amneal Pharmaceuticals' Share-based Compensation soared by 51.31% in 2022 and then fell by 23.71% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Share-based Compensation (Quarterly) stood at $7.7 million in 2021, then rose by 1.15% to $7.8 million in 2022, then fell by 23.71% to $6.0 million in 2023, then climbed by 20.69% to $7.2 million in 2024, then climbed by 15.57% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, $8.3 million for Q2 2025, and $7.3 million during Q1 2025.